AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 9, 2022
The most effective way for people with diabetes to deliver insulin is also incredibly intrusive. Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance.
Velocity Clinical Research
JANUARY 16, 2024
Reviewing data from Phase 2 clinical trials for basal insulins icodec and efsitora, as well as the Phase 3 icodec program, the article indicates that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a similar risk of hypoglycemia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Velocity Clinical Research
JUNE 27, 2023
Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A
XTalks
APRIL 29, 2021
Multiple studies have confirmed that conducting clinical trials with a diverse range of ethnicities, genders, ages, and lifestyles is essential, since these factors can impact a treatment’s effectiveness among different groups. Despite this, ethnic minorities are underrepresented in clinical trials.
XTalks
DECEMBER 15, 2022
In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. ” The trial DIAGNODE-3 is approved and currently recruiting patients in eight countries in Europe. . The US Clinical Hold on the Diamyd Trial is Lifted, Now What?
XTalks
SEPTEMBER 17, 2020
In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. Verifying the biomarker’s clinical validity for use as a surrogate endpoint in rare disease research is another hurdle which is generally a longer-term goal.
Pharmaceutical Technology
JANUARY 30, 2023
The FDA even suggested that the company should conduct a multiregional clinical trial, as the drug’s pivotal trial was conducted only in China, where it is currently marketed for multiple oncology indications. The drug increases insulin synthesis and release. months longer on the treatment.
Expert insights. Personalized for you.
187 
Let's personalize your content